Free shipping on all orders over $ 500

BGP-15 2HCl

Cat. No. M9253
BGP-15 2HCl Structure
Size Price Availability Quantity
10mg USD 120  USD120 In stock
25mg USD 240  USD240 In stock
50mg USD 438  USD438 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

BGP-15 protects against nephrotoxicity of cisplatin without compromising its antitumor activity. BGP-15 inhibits caspase-independent programmed cell death in acetaminophen-induced liver injury. Moreover, BGP-15 was found to prevent imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases.

In vivo, BGP-15 (10 and 30 mg/kg) increases insulin sensitivity by 50% and 70%, respectively, in cholesterol-fed but not in normal rabbits. After 5 days of treatment with BGP-15, the glucose infusion rate is increased in a dose-dependent manner in genetically insulin-resistant GK rats. The most effective dose is 20 mg/kg, which shows a 71% increase in insulin sensitivity compared to control group. BGP-15 treatment is associated with a reduced PR interval in the HF+AF model.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 351.27
Formula C14H24Cl2N4O2
CAS Number 66611-37-8
Purity >98%
Solubility DMSO 10 mg/mL (Need warming)
Storage at -20°C

[1] Sapra G, et al. Nat Commun. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice.

[2] Literati-Nagy B, et al. Metab Syndr Relat Disord. Improvement of insulin sensitivity by a novel dru-g candidate, BGP-15, in different animal studies.

[3] Sarszegi Z, et al. Mol Cell Biochem. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases.

Related PARP Products
Fluzoparib (SHR3162)

Fuzuopali is a poly (ADP-ribose) polymerase inhibitor (PARP) inhibitor with IC50 of 1.46±0.72 nM for a cell‐free enzymatic assay, with superior antitumor activity.


AZD5305 is a potent and oral active, second-generation PARP (highly selective PARP1) inhibitor.


BRCA1-IN-2 is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1, with IC50 of 0.31 μM and Kd of 0.3 μM.


RBN-2397 is a potent and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM).


Pamiparib (BGB-290) is an orally active, potent, highly selective inhibitor of PARP1 and PARP2 with IC50 values of 0.9 nM and 0.5 nM, respectively.

Abmole Inhibitor Catalog 2017

Keywords: BGP-15 2HCl supplier, PARP, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.